Rep. Val T. Hoyle Sells Off Shares of Boston Scientific Corporation (NYSE:BSX)

Key Points

• Representative Val T. Hoyle sold shares of Boston Scientific Corporation (NYSE:BSX) valued between $1,001 and $15,000, and this transaction was disclosed on October 10th.
• Boston Scientific recently reported a net revenue increase of 22.8% year-over-year, with earnings per share hitting $0.75, exceeding estimates, and providing future earnings guidance of $0.700-0.720 for Q3 2025.
• Institutional investors hold 89.07% of Boston Scientific's stock, indicating strong institutional interest and investment in the company.

Representative Val T. Hoyle (D-Oregon) recently sold shares of Boston Scientific Corporation NYSE: BSX. In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on September 23rd. The trade occurred in the Representative's "FIDELITY ROLLOVER IRA" account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Marriott International NASDAQ: MAR on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Transdigm Group NYSE: TDG on 9/23/2025.
• Sold $1,001 - $15,000 in shares of H&R Block NYSE: HRB on 9/23/2025.
• Sold $1,001 - $15,000 in shares of NIKE NYSE: NKE on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Bank of New York Mellon NYSE: BK on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Cisco Systems NASDAQ: CSCO on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Capital One Financial NYSE: COF on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Pentair NYSE: PNR on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Heico NYSE: HEI.A on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Target NYSE: TGT on 9/23/2025.

Boston Scientific Stock Down 1.9%

Shares of NYSE:BSX opened at $95.41 on Friday. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a market cap of $141.38 billion, a PE ratio of 56.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. The firm has a 50 day simple moving average of $101.98 and a 200 day simple moving average of $101.87.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Institutional Trading of Boston Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the second quarter valued at $26,000. Sound Income Strategies LLC increased its holdings in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Steph & Co. acquired a new position in shares of Boston Scientific in the third quarter valued at $25,000. 1248 Management LLC acquired a new position in shares of Boston Scientific in the first quarter valued at $26,000. Finally, Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the first quarter valued at $27,000. 89.07% of the stock is owned by institutional investors.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $17,972,457 in the last ninety days. Company insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on BSX shares. Barclays increased their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research note on Thursday, October 2nd. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Leerink Partners lifted their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the company an "outperform" rating in a report on Wednesday, October 1st. Finally, Canaccord Genuity Group raised their price objective on shares of Boston Scientific from $131.00 to $132.00 and gave the company a "buy" rating in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $120.71.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon's 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon's 4th Congressional District. She declared candidacy for the 2026 election. Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.